Volltextsuche nutzen
- versandkostenfrei ab € 30,–
- 11x in Wien, NÖ und Salzburg
- 6 Mio. Bücher
- facultas
- Detailansicht
Phase II Clinical Development of New Drugs
Taschenbuch
131,99€
inkl. gesetzl. MwSt.
Herstellung bei AnforderungVersandkostenfreibestellen in Österreich
Deutschland: € 10,00
EU & Schweiz: € 20,00
EU & Schweiz: € 20,00
In den Warenkorb
Click & Collect
Artikel online bestellen und in der Filiale abholen.
Derzeit in keiner facultas Filiale lagernd. Jetzt online bestellen!Artikel online bestellen und in der Filiale abholen.
Artikel in den Warenkorb legen, zur Kassa gehen und Wunschfiliale auswählen. Lieferung abholen und bequem vor Ort bezahlen.
Auf die Merkliste
Veröffentlicht 2018, von Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri bei Springer Singapore
ISBN: 978-981-135-074-0
Auflage: 1. Auflage
Reihe: ICSA Book Series in Statistics
XVII, 241 Seiten
XVII, 241 p. 25 illus., 17 illus. in color.
23.5 cm x 15.5 cm
This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it ...
Beschreibung
This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.
Zitat aus einer Besprechung
“It provides a hands-on approach to each subject, and the necessary statistical background is presented in the most non-mathematical way possible. … Throughout the book, the scope of each subject is well defined, and if the reader has the need for further support, useful references are helpfully recommended. … I would strongly recommend this book to anyone working in clinical development or with an interest in this field, regardless of their background.” (David Manteigas, ISCB News, iscb.info, Issue 65, June, 2018)
This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.
Zitat aus einer Besprechung
“It provides a hands-on approach to each subject, and the necessary statistical background is presented in the most non-mathematical way possible. … Throughout the book, the scope of each subject is well defined, and if the reader has the need for further support, useful references are helpfully recommended. … I would strongly recommend this book to anyone working in clinical development or with an interest in this field, regardless of their background.” (David Manteigas, ISCB News, iscb.info, Issue 65, June, 2018)